UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2020
Commission File Number 001-15170
GlaxoSmithKline plc
(Translation of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Sir Jonathan Symonds | |||
| b) | Position/status | Non-Executive Chairman | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |||
| b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2020 to 31 March 2020 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £16.93 | 2,584.170 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2020-04-29 | |||
| f) | Place of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr Vindi Banga | |||
| b) | Position/status | Senior Independent Non-Executive Director | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |||
| b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2020 to 31 March 2020 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £16.93 | 646.043 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2020-04-29 | |||
| f) | Place of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dr Vivienne Cox | |||
| b) | Position/status | Independent Non-Executive Director | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |||
| b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2020 to 31 March 2020 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £16.93 | 461.459 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2020-04-29 | |||
| f) | Place of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms Lynn Elsenhans | |||
| b) | Position/status | Independent Non-Executive Director | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |||
| b) | Nature of the transaction | Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2020 to 31 March 2020 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $42.41 | 717.329 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2020-04-29 | |||
| f) | Place of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dr Laurie Glimcher | |||
| b) | Position/status | Independent Non-Executive Director | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |||
| b) | Nature of the transaction | Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2020 to 31 March 2020 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $42.41 | 1,176.571 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2020-04-29 | |||
| f) | Place of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dr Jesse Goodman | |||
| b) | Position/status | Independent Non-Executive Director | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |||
| b) | Nature of the transaction | Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2020 to 31 March 2020 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $42.41 | 370.051 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2020-04-29 | |||
| f) | Place of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms Judy Lewent | |||
| b) | Position/status | Independent Non-Executive Director | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |||
| b) | Nature of the transaction | Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2020 to 31 March 2020 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $42.41 | 389.027 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2020-04-29 | |||
| f) | Place of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr Urs Rohner | |||
| b) | Position/status | Independent Non-Executive Director | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |||
| b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2020 to 31 March 2020 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £16.93 | 609.126 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2020-04-29 | |||
| f) | Place of the transaction | N/A | |||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GlaxoSmithKline plc | |
| (Registrant) | |
| Date: May 04, 2020 | |
By:/s/ VICTORIA WHYTE -------------------------- | |
| Victoria Whyte | |
| Authorised Signatory for and on | |
| behalf of GlaxoSmithKline plc |